References Kaminetsky J, Werner M, Fontenot G, Wiehle RD
De manera crtica, la curva de prdida de peso a las 48 semanas an no haba alcanzado una meseta lo que sugiere que una mayor duracin del tratamiento podra producir reducciones an mayores
In a Phase II study, the CD19-targeting CAR-T mivocabtagene autoleucel demonstrated significant improvement in individuals with stiff person syndrome, with a 46% median improvement in a timed 25-foot walk at week 16 and sustained B-cell depletion without high-grade cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome
These same strategies apply to other weight loss medications in the same category
Motivated behavior For the evaluation of carry-over effects, the statistical test for comparing outcome distribution of the two groups at baseline in the second period was not significant ( p = 0.96), indicating no carry over effect